US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Navan is offering 36.9mm shares at $24-$26 and will debut on October 31st invoking a 20-day effectiveness rule during the current government shutdown.</li>
<li>Their revenue grew 33% year-over-year from $402 million in fiscal 2024 to $537 million in fiscal 2025.</li>
<li>Navan (formerly TripActions) is led by two high-profile co-founders who previously sold had a business acquired in this space.</li>
</ul>


Navan is offering 36.9mm shares at $24-$26 and will debut on October 31st invoking a 20-day effectiveness rule during the current government shutdown.
Their revenue grew 33% year-over-year from $402 million in fiscal 2024 to $537 million in fiscal 2025.
Navan (formerly TripActions) is led by two high-profile co-founders who previously sold had a business acquired in this space.


Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

MapLight Therapeutics / Equity Capital Markets

<ul>
<li>Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. </li>
<li>Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. </li>
<li>The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.</li>
</ul>


Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. 
Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. 
The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.


Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

<ul>
<li>The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.</li>
<li>Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.</li>
<li>Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.</li>
</ul>


The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.
Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.
Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.


Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

United States

MapLight Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on improving the lives of patients suffering from debilitating central nervous system disorders. MapLight Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MapLight Therapeutics (MPLT US)

Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

​Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

​Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

​Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.

IPO Boutique

Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.